SLC5A1 and type 2 diabetes mellitus: Several inhibitors, such as empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and bexagliflozin, SGLT2 inhibitors have been approved for managing adult patients with type 2 diabetes (Padda et al., 2022) but not type 1 diabetes, and sotagliflozin is recently approved as a dual SGLT1/SGLT2 inhibitor for treating heart failure (Packer, 2023).